Title: Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in
inflammatory bowel disease patients
Version: 2 Date: 25 Dec 2023
Reviewer:  Ilhami Yüksel
Reviewer's report:
Again.
In this prospective observational study, the authors aimed to determine the clinical
utility of an antibody-based strategy to diagnose IBS/IBS-D in IBD patients that present with
chronic diarrhea despite endoscopic remission. They have 4 groups, which include Active IBD,
Quiescent IBD, Diarrhea-predominant irritable bowel syndrome and Healthy controls. In the
literature, large cohort study showed that higher levels of antibodies to CdtB and vinculin were
detected in IBS-D subjects as compared to IBD subjects and healthy controls. However, in the
presented study there is no difference between diarrhea-predominant irritable bowel syndrome
and
healthy controls in terms of anti-CdtB and anti-vinculin antibodies in the Brazilian population.
Therefore, in the Brazilian IBD population, such markers could not be used to differentiate
between active and quiescent IBD or between IBS and IBS-D.
Title: Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in
inflammatory bowel disease patients
Version: 2 Date: 25 Dec 2023
Reviewer:  Ilhami Yüksel
Reviewer's report:
Again.
In this prospective observational study, the authors aimed to determine the clinical
utility of an antibody-based strategy to diagnose IBS/IBS-D in IBD patients that present with
chronic diarrhea despite endoscopic remission. They have 4 groups, which include Active IBD,
Quiescent IBD, Diarrhea-predominant irritable bowel syndrome and Healthy controls. In the
literature, large cohort study showed that higher levels of antibodies to CdtB and vinculin were
detected in IBS-D subjects as compared to IBD subjects and healthy controls. However, in the
presented study there is no difference between diarrhea-predominant irritable bowel syndrome
and
healthy controls in terms of anti-CdtB and anti-vinculin antibodies in the Brazilian population.
Therefore, in the Brazilian IBD population, such markers could not be used to differentiate
between active and quiescent IBD or between IBS and IBS-D.
Please review this paper.
user
Title: Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in
inflammatory bowel disease patients
Version: 2 Date: 25 Dec 2023
Reviewer:  Ilhami Yüksel
Reviewer's report:
Again.
In this prospective observational study, the authors aimed to determine the clinical
utility of an antibody-based strategy to diagnose IBS/IBS-D in IBD patients that present with
chronic diarrhea despite endoscopic remission. They have 4 groups, which include Active IBD,
Quiescent IBD, Diarrhea-predominant irritable bowel syndrome and Healthy controls. In the
literature, large cohort study showed that higher levels of antibodies to CdtB and vinculin were
detected in IBS-D subjects as compared to IBD subjects and healthy controls. However, in the
presented study there is no difference between diarrhea-predominant irritable bowel syndrome
and
healthy controls in terms of anti-CdtB and anti-vinculin antibodies in the Brazilian population.
Therefore, in the Brazilian IBD population, such markers could not be used to differentiate
between active and quiescent IBD or between IBS and IBS-D.
assistant